ICD-10 code D75.A for Glucose-6-phosphate dehydrogenase (G6PD) deficiency without anemia is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism. Subscribe to Codify and get the code details in a flash.
ICD-10-CM Code for Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency D55.0 ICD-10 code D55.0 for Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism.
G6PD deficiency, an X-linked disorder, is the most common enzymatic disorder of red blood cells in humans, affecting more than 400 million people worldwide. The clinical expression of G6PD variants encompasses a spectrum of hemolytic syndromes.
Levels of G6PD are higher in the newborn than they are in the adult. When high levels are seen in older patients, it invariably reflects the presence of a young red blood cell population with reticulocytosis. See table. See table. See table. G6PD hemolysis is associated with formation of Heinz bodies in peripheral red blood cells.
Names and CodesCondition:1Glucose-6-phosphate dehydrogenase deficiencyICD-9-CM Code:5282.2—Anemias due to disorders of glutathione metabolismICD-10-CM Code:6D55.0—Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency3 more rows•Sep 14, 2009
A G6PD test is a blood draw to check levels of glucose-6-phosphate dehydrogenase (G6PD). G6PD is a protein that supports red blood cell function. If you have low G6PD, you may develop hemolytic anemia, which occurs when your body destroys red blood cells faster than it makes them.
What is a G6PD test? This test measures the amount of G6PD in the blood. G6PD stands for glucose-6-phosphate dehydrogenase, an enzyme that helps red blood cells work properly. Red blood cells move oxygen from your lungs to every cell in your body.
Collapse Section. Glucose-6-phosphate dehydrogenase deficiency is a genetic disorder that affects red blood cells, which carry oxygen from the lungs to tissues throughout the body. In affected individuals, a defect in an enzyme called glucose-6-phosphate dehydrogenase causes red blood cells to break down prematurely.
Here are some general results: A normal test result tells your healthcare provider about G6PD activity in your blood cells. A normal—or no G6PDD—result for adults is 5.5 to 20.5 units/gram of hemoglobin. Less than 10% of normal means that you have severe deficiency and chronic hemolytic anemia.
The diagnosis of G6PD deficiency is made by a quantitative spectrophotometric analysis or, more commonly, by a rapid fluorescent spot test detecting the generation of NADPH from NADP. The test is positive if the blood spot fails to fluoresce under ultraviolet light.
G6PD deficiency and COVID-19 vaccines Like routine vaccines, COVID-19 vaccines can be safely administered to people with G6PD deficiency. Clinical trials and real-world evidence have not identified any specific concerns regarding COVID-19 vaccines and people with G6PD deficiency.
However, deficiency of G6PD was found to be related to other autoimmune diseases. A reseach on Sudanese vitiligo patients revealed an excess deficiency of G6PD compared to the controls [11]. Type 1 diabetic patients with G6PD deficiency also suffer from accelerated microvascular complications such as retinopathy [12].
G6PD can cause hemolytic anemia. This is when the red blood cells break down faster than they are made. Symptoms of hemolytic anemia include: Pale skin.
G6PD hemolysis is associated with formation of Heinz bodies in peripheral red blood cells. It is the older erythrocytes that are most G6PD-deficient in affected individuals. These cells are first eliminated in a hemolytic crisis. The younger cells and reticulocytes contain more G6PD.
With the most prevalent G6PD variants (G6PD A- and G6PD Mediterranean), hemolysis is induced in children and adults by the sudden destruction of older, more deficient erythrocytes after exposure to drugs having a high redox potential (including the antimalarial drug primaquine and certain sulfa drugs) or to fava beans, selected infections, or metabolic abnormalities. In the neonate with G6PD deficiency, however, decreased bilirubin elimination may play an important role in the development of jaundice.
Levels of G6PD are higher in the newborn than they are in the adult. When high levels are seen in older patients, it invariably reflects the presence of a young red blood cell population with reticulocytosis.
G6PD deficiency should be suspected in any subject with an episode of nonimmune hemolytic anemia, especially if occurring after drug ingestion, infection, or an episode of diabetic ketoacidosis.
G6PD hemolysis is associated with formation of Heinz bodies in peripheral red blood cells. It is the older erythrocytes that are most G6PD-deficient in affected individuals. These cells are first eliminated in a hemolytic crisis. The younger cells and reticulocytes contain more G6PD.
With the most prevalent G6PD variants (G6PD A- and G6PD Mediterranean), hemolysis is induced in children and adults by the sudden destruction of older, more deficient erythrocytes after exposure to drugs having a high redox potential (including the antimalarial drug primaquine and certain sulfa drugs) or to fava beans, selected infections, or metabolic abnormalities. In the neonate with G6PD deficiency, however, decreased bilirubin elimination may play an important role in the development of jaundice.
False normal results after hemolysis may occur. See Additional Information. Levels of G6PD are higher in the newborn than they are in the adult. When high levels are seen in older patients, it invariably reflects the presence of a young red blood cell population with reticulocytosis.
G6PD deficiency should be suspected in any subject with an episode of nonimmune hemolytic anemia, especially if occurring after drug ingestion, infection, or an episode of diabetic ketoacidosis.
Glucose-6-Phosphate Dehydrogenase, Quantitative - Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzyme deficiency in the world, affecting an estimated 400 million people worldwide [1]. It is more common in people of African, Mediterranean, and Asian descent.
G6PD deficiency is an X-linked genetic disorder and, in general, affects males more than females. Severity ranges from mild to severe subtypes. Newborns with G6PD deficiency may have prolonged and more pronounced neonatal jaundice than other newborns.